I agree, Invictus has been poorly run. The company will be very lucky to be able to restructure itself well enough to continue business without further downsizing of some sort during the CCAA proceedings. However, there is a great deal of value in the infrastructure that remains.
Acreage Pharms has three buildings (with a variety of licenses and abilities as I mentioned in my last post). AB Labs has another two buildings (with cultivating and sales licenses also). Phase three at AP is built to EUGMP Standards although is yet to be licensed for that.
There is a great deal of value above the C $6M market cap that is currently showing. By March 10, 2020 Invictus has to announce whether it has any bids so far for the full or partial sale of the company. By April 17, 2020 Phase 1 of the bidding process will end and at that time the company could decide it is in the best interests of shareholders to accept a possible bid. If not, then a second wave of bids will be accepted until May 19, 2020.
I would venture that if there are any bids at all above the current market cap then the Share price is very like to rise. Also, if there are bids by any company known to have the capital to infuse into Invictus to keep it a going concern again this could easily get the SP back to a more reasonable amount.
All the news related to the Court approved restructuring/ sale of the company is updated regularly at the following website: https://www.pwc.com/ca/invictus
This is a good site to find all the relevant info currently important to this stock.
IMO, whether the company manages to restructure or not, its very undervalued.
News 
Market Data 
Discover 
